Imeik Technology Development Co.,Ltd.

SZSE:300896 Stock Report

Market Cap: CN¥56.3b

Imeik Technology DevelopmentLtd Valuation

Is 300896 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300896 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300896 (CN¥186.75) is trading below our estimate of fair value (CN¥237.31)

Significantly Below Fair Value: 300896 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300896?

Key metric: As 300896 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300896. This is calculated by dividing 300896's market cap by their current earnings.
What is 300896's PE Ratio?
PE Ratio27.8x
EarningsCN¥2.03b
Market CapCN¥56.26b

Price to Earnings Ratio vs Peers

How does 300896's PE Ratio compare to its peers?

The above table shows the PE ratio for 300896 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.2x
002252 Shanghai RAAS Blood Products
26.1x18.2%CN¥47.7b
300122 Chongqing Zhifei Biological Products
17.9x33.3%CN¥65.9b
688278 Xiamen Amoytop Biotech
40.3x31.7%CN¥29.9b
600161 Beijing Tiantan Biological Products
32.5x19.7%CN¥41.4b
300896 Imeik Technology DevelopmentLtd
27.8x16.5%CN¥56.3b

Price-To-Earnings vs Peers: 300896 is good value based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (29.2x).

Price to Earnings Ratio vs Industry

How does 300896's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300896 27.8xIndustry Avg. 32.7xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300896 is good value based on its Price-To-Earnings Ratio (27.8x) compared to the CN Biotechs industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is 300896's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300896 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.8x
Fair PE Ratio30.7x

Price-To-Earnings vs Fair Ratio: 300896 is good value based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (30.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300896 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥186.75
CN¥266.90
+42.9%
27.0%CN¥472.14CN¥201.00n/a11
Dec ’25CN¥211.90
CN¥267.63
+26.3%
26.7%CN¥472.14CN¥201.00n/a11
Nov ’25CN¥211.02
CN¥268.23
+27.1%
26.8%CN¥472.14CN¥201.00n/a12
Oct ’25CN¥235.60
CN¥264.39
+12.2%
29.0%CN¥472.14CN¥180.00n/a12
Sep ’25CN¥144.96
CN¥282.99
+95.2%
31.8%CN¥478.07CN¥180.00n/a13
Aug ’25CN¥172.98
CN¥312.90
+80.9%
26.0%CN¥478.07CN¥207.00n/a13
Jul ’25CN¥173.66
CN¥307.52
+77.1%
22.0%CN¥478.07CN¥228.57n/a12
Jun ’25CN¥201.13
CN¥307.52
+52.9%
22.0%CN¥478.07CN¥228.57n/a12
May ’25CN¥214.80
CN¥315.86
+47.0%
21.0%CN¥478.07CN¥228.57n/a12
Apr ’25CN¥249.94
CN¥324.60
+29.9%
19.5%CN¥478.07CN¥269.29n/a11
Mar ’25CN¥229.44
CN¥326.35
+42.2%
24.8%CN¥478.07CN¥221.43n/a11
Feb ’25CN¥201.70
CN¥338.17
+67.7%
25.1%CN¥478.07CN¥221.43n/a11
Jan ’25CN¥210.24
CN¥372.57
+77.2%
20.1%CN¥478.07CN¥221.43n/a11
Dec ’24CN¥212.86
CN¥395.57
+85.8%
10.9%CN¥478.07CN¥317.14CN¥211.9010
Nov ’24CN¥231.14
CN¥405.78
+75.6%
11.1%CN¥478.07CN¥317.14CN¥211.0211
Oct ’24CN¥278.76
CN¥451.10
+61.8%
6.1%CN¥478.57CN¥397.86CN¥235.6011
Sep ’24CN¥313.57
CN¥451.10
+43.9%
6.1%CN¥478.57CN¥397.86CN¥144.9611
Aug ’24CN¥326.20
CN¥465.84
+42.8%
7.8%CN¥545.00CN¥397.86CN¥172.9811
Jul ’24CN¥317.82
CN¥481.59
+51.5%
5.0%CN¥545.00CN¥450.00CN¥173.669
Jun ’24CN¥325.43
CN¥489.11
+50.3%
6.0%CN¥545.00CN¥450.00CN¥201.138
May ’24CN¥388.55
CN¥497.26
+28.0%
7.3%CN¥562.50CN¥450.00CN¥214.809
Apr ’24CN¥399.11
CN¥496.31
+24.4%
7.5%CN¥562.50CN¥444.29CN¥249.949
Mar ’24CN¥421.43
CN¥475.31
+12.8%
11.8%CN¥563.36CN¥432.25CN¥229.447
Feb ’24CN¥431.43
CN¥475.31
+10.2%
11.8%CN¥563.36CN¥432.25CN¥201.707
Jan ’24CN¥404.54
CN¥470.89
+16.4%
9.9%CN¥562.50CN¥432.25CN¥210.248
Dec ’23CN¥355.18
CN¥470.89
+32.6%
9.9%CN¥562.50CN¥432.25CN¥212.868

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 00:05
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Imeik Technology Development Co.,Ltd. is covered by 32 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethan CuiBofA Global Research
Jian Jun ZouChasing Securities
Xiyue ZhangChasing Securities